AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34048587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum ferritin levels (<100 ng/mL)
Number of subjects: 0
Study 34048587 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum ferritin and IL-6 levels
Number of subjects: 0
Study 34048587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels above 194 ng/mL
Number of subjects: 0
Study 34048587 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal ferritin levels for cardiovascular mortality reduction
Number of subjects: 0
Study 32617701 — intervention group
Group type: EXPERIMENTAL
Intervention: American ginseng 1000 mg per day for 8 weeks
Number of subjects: 32
Study 32617701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 34778937 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (PH6) activated with violet LED (PH6V)
Number of subjects: 40
Study 34778937 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (PH6) activated with blue LED (PH6A)
Number of subjects: 40
Study 34778937 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (PH6) without light activation
Number of subjects: 40
Study 34778937 — intervention group
Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (PH35) - control
Number of subjects: 40
Study 36056351 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 2482
Study 33155188 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest algorithm
Number of subjects: 84977
Study 33155188 — intervention group
Group type: COMPARATOR
Intervention: Other machine learning methods (Lasso penalized linear regression, Decision tree, Boosting regression, Bagging regression, Support vectors, Neural network)
Number of subjects: 84977
Study 34881963 — intervention group
Group type: EXPERIMENTAL
Intervention: Recitation of nursery rhymes (10 sessions, 2 months)
Number of subjects: 0
Study 34881963 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to nursery rhymes (alphabet-related)
Number of subjects: 0
Study 34881963 — intervention group
Group type: EXPERIMENTAL
Intervention: Recitation groups (both alphabet-related and unrelated)
Number of subjects: 0
Study 34881963 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening groups (non-alphabet-related)
Number of subjects: 0
Study 34881963 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonlinguistic activities)
Number of subjects: 0
Study 33534516 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly empathic communication email reminders
Number of subjects: 0
Study 33534516 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic communication quick reference guide
Number of subjects: 0
Study 33534516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both email reminders and quick reference guide
Number of subjects: 0
Study 33534516 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 0
Study 33403940 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg of extended-release niacin orally once daily for 24 weeks
Number of subjects: 20
Study 35301911 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized Cycle Ergometer (MCE)
Number of subjects: 60
Study 35301911 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Functional Exercise (HIFE)
Number of subjects: 60
Study 35301911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MCE and HIFE
Number of subjects: 60
Study 35301911 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 60
Study 33885776 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-initiated Kangaroo Mother Care (ciKMC) until 28 days after birth, including promotion and support of skin-to-skin contact and exclusive breastfeeding through home visits.
Number of subjects: 1950
Study 33885776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ciKMC).
Number of subjects: 1950
Study 32341641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 µg twice daily
Number of subjects: 781
Study 32341641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 781
Study 32696585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib (10 mg single oral dose)
Number of subjects: 0
Study 35311716 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT) with Lumosity software
Number of subjects: 39
Study 35311716 — intervention group
Group type: COMPARATOR
Intervention: Conventional cognitive training
Number of subjects: 39
Study 32186238 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated vacuum
Number of subjects: 12
Study 32186238 — intervention group
Group type: COMPARATOR
Intervention: Suction suspension
Number of subjects: 12
Study 616709407 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 34
Study 616709407 — intervention group
Group type: COMPARATOR
Intervention: FS‐LASIK
Number of subjects: 34
Study 34624810 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (TWE)
Number of subjects: 450
Study 34624810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (TWM)
Number of subjects: 450
Study 34624810 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 450
Study 34193262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Lactobacillus reuteri and ω‐3 fatty acid treatment (double-treatment)
Number of subjects: 63
Study 34193262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (single treatment)
Number of subjects: 63
Study 34193262 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acid (single treatment)
Number of subjects: 63
Study 34193262 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 63
Study 35704085 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐vitamin supplementation (400 µg folic acid and 500 µg vitamin B12 daily for 2 years)
Number of subjects: 191
Study 35704085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 2 years)
Number of subjects: 191
Study 33900319 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified alcohol-free beer (16.5 g isomaltulose and 5.28 g resistant maltodextrin per day)
Number of subjects: 14
Study 33900319 — intervention group
Group type: COMPARATOR
Intervention: Regular alcohol-free beer
Number of subjects: 14
Study 32719973 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision system and mobile application with expert support
Number of subjects: 0
Study 32719973 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 36187572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model based on four variables: left atrial diameter, left ventricular ejection fraction, type of atrial fibrillation, systemic inflammation score.
Number of subjects: 485
Study 33390191 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention to increase adherence to nebuliser treatments, details on dosage and duration not specified.
Number of subjects: 0
Study 33390191 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, but the intervention is being tested against standard care in a randomised controlled trial.
Number of subjects: 0
Study 32037213 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional fluid management group (TFG)
Number of subjects: 130
Study 32037213 — intervention group
Group type: COMPARATOR
Intervention: Oral fluid management group (OFG)
Number of subjects: 130
Study 35988522 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 % povidone-iodine (PVP-I)
Number of subjects: 38
Study 35988522 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 % hydrogen peroxide (H2O2)
Number of subjects: 38
Study 35988522 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 % chlorhexidine (CHX)
Number of subjects: 38
Study 35988522 — intervention group
Group type: COMPARATOR
Intervention: Sodium Chloride 0.9 % (placebo)
Number of subjects: 38
Study 34273139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0
Study 33020951 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash with anti-discoloration system
Number of subjects: 38
Study 33020951 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash without anti-discoloration system
Number of subjects: 38
Study 33020951 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 38
Study 35615299 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course antibiotics (7 days)
Number of subjects: 604
Study 35615299 — intervention group
Group type: COMPARATOR
Intervention: Conventional course antibiotics (14 days)
Number of subjects: 604
Study 33721922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost and culturally acceptable treatment focusing on quality-of-life issues.
Number of subjects: 0
Study 33721922 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative model of treatment incorporating traditional practices and community support.
Number of subjects: 0
Study 35027013 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) using the WalkAide® device for 12 weeks
Number of subjects: 25
Study 35027013 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 25
Study 35027013 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (AFO/adapted shoes) for 12 weeks
Number of subjects: 25
Study 33764803 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin Converting Enzyme (ACE) inhibitors
Number of subjects: 0
Study 33764803 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin‐2 receptor blockers (ARBs)
Number of subjects: 0
Study 32500675 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSA with sufentanil
Number of subjects: 120
Study 32500675 — intervention group
Group type: COMPARATOR
Intervention: PCSA with morphine
Number of subjects: 120
Study 34315492 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding counseling using a socio‐ecological framework
Number of subjects: 80
Study 34315492 — intervention group
Group type: COMPARATOR
Intervention: Standard infant feeding information and counseling on immunizations (Control)
Number of subjects: 80
Study 32476277 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐SZ‐IFX
Number of subjects: 650
Study 32476277 — intervention group
Group type: COMPARATOR
Intervention: IFX‐EU
Number of subjects: 650
Study 35443108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib and azacitidine
Number of subjects: 146
Study 35443108 — intervention group
Group type: COMPARATOR
Intervention: Placebo and azacitidine
Number of subjects: 146
Study 34102868 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SWT plus a progressive exercise program
Number of subjects: 90
Study 34102868 — intervention group
Group type: COMPARATOR
Intervention: Placebo SWT plus a progressive exercise program
Number of subjects: 90
Study 32404130 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily one-way text message intervention for 6 months
Number of subjects: 94
Study 32404130 — intervention group
Group type: COMPARATOR
Intervention: Standard care without text message reminders for 6 months
Number of subjects: 94
Study 33306283 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib plus Remdesivir
Number of subjects: 1033
Study 33306283 — intervention group
Group type: COMPARATOR
Intervention: Control (Remdesivir only)
Number of subjects: 1033
Study 33306283 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib plus Remdesivir (for patients on high-flow oxygen or noninvasive ventilation)
Number of subjects: 1033
Study 33306283 — intervention group
Group type: COMPARATOR
Intervention: Control (for patients on high-flow oxygen or noninvasive ventilation)
Number of subjects: 1033
Study 35928285 — intervention group
Group type: EXPERIMENTAL
Intervention: PROQOL (Patient-Reported Outcome Quality of Life tool)
Number of subjects: 383
Study 35928285 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 383
Study 35928285 — intervention group
Group type: EXPERIMENTAL
Intervention: PROQOL
Number of subjects: 383
Study 33351076 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal Impulse and Rotor Modulation (FIRM) group
Number of subjects: 51
Study 33351076 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary Vein Isolation (PVI) group
Number of subjects: 51
Study 33351076 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM group
Number of subjects: 51
Study 33351076 — intervention group
Group type: COMPARATOR
Intervention: PVI group
Number of subjects: 51
Study 36127661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide plus chlorthalidone
Number of subjects: 32
Study 34119811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (used in one or several sessions, alone or as an adjunct, reinforced with daily self-hypnosis with or without audio tapes)
Number of subjects: 0
Study 34119811 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33351072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sIPV
Number of subjects: 1422
Study 33351072 — intervention group
Group type: COMPARATOR
Intervention: Conventional IPV (cIPV)
Number of subjects: 1422
Study 32424462 — intervention group
Group type: EXPERIMENTAL
Intervention: AFG
Number of subjects: 36
Study 32424462 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐PRF
Number of subjects: 36
Study 32424462 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 35605188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib (100 mg once daily)
Number of subjects: 0
Study 35605188 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib (250 mg twice a day)
Number of subjects: 0
Study 33098995 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2 weekly) plus Olaparib (100 mg twice daily for 12 weeks)
Number of subjects: 107
Study 33098995 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus Carboplatinum (AUC 2 weekly for 12 weeks)
Number of subjects: 107
Study 33098995 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Olaparib
Number of subjects: 107
Study 32073673 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron status assessment (haemoglobin concentration, serum iron, serum ferritin, transferrin saturation)
Number of subjects: 170
Study 32073673 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II and III iron depletion
Number of subjects: 170
Study 32073673 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin as a biomarker
Number of subjects: 170
Study 35861805 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 0
Study 35861805 — intervention group
Group type: COMPARATOR
Intervention: Traditional metric-modified Rankin Scale score 0-2
Number of subjects: 0
Study 34278665 — intervention group
Group type: EXPERIMENTAL
Intervention: Protaper Universal (PTU)
Number of subjects: 120
Study 34278665 — intervention group
Group type: COMPARATOR
Intervention: Reciproc Blue (RB)
Number of subjects: 120
Study 34278665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 32159519 — intervention group
Group type: EXPERIMENTAL
Intervention: MeMo Web app (active MeMo group, n=9)
Number of subjects: 46
Study 32159519 — intervention group
Group type: EXPERIMENTAL
Intervention: MeMo Web app (nonactive MeMo group, n=13)
Number of subjects: 46
Study 32159519 — intervention group
Group type: COMPARATOR
Intervention: Control group (not using MeMo)
Number of subjects: 46
Study 33855585 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib monotherapy
Number of subjects: 47
Study 33855585 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-6 levels
Number of subjects: 47
Study 33855585 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-8 levels
Number of subjects: 47
Study 33855585 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6 cut-off value of 8.58 pg/mL
Number of subjects: 47
Study 33855585 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-8 cut-off value of 57.9 pg/mL
Number of subjects: 47
Study 33855585 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 and IL-8 as independent predictors of OS
Number of subjects: 47
Study 33408308 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/Nedaplatin (60/80 mg/m2/day)
Number of subjects: 36
Study 33408308 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (70 mg/m2/day)
Number of subjects: 36
Study 32621073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (dopamine D2 agonist)
Number of subjects: 30
Study 32621073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35889902 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS
Number of subjects: 24
Study 35889902 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS + EX
Number of subjects: 24
Study 35792744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (10 µM)
Number of subjects: 3
Study 35792744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (30 µM)
Number of subjects: 3
Study 35792744 — intervention group
Group type: COMPARATOR
Intervention: Control (0.8 dS m‐1 ECw)
Number of subjects: 3
Study 35792744 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt stress (1.6, 2.4, and 3.2 dS m‐1 ECw)
Number of subjects: 3
Study 32692751 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-calorie food supplement offered daily to pregnant and lactating women (2.09 MJ energy and 20-25 g protein) and their offspring (1.25 MJ energy and 8-10 g protein) until the age of six years.
Number of subjects: 1826
Study 94188401 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and intervention protocol for fall prevention and mobility improvement
Number of subjects: 31
Study 94188401 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and intervention protocol
Number of subjects: 31
Study 35986475 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 cm PID with 1.02 mm thick Al alloy filter and rectangular collimator
Number of subjects: 125
Study 35986475 — intervention group
Group type: COMPARATOR
Intervention: Standard intraoral radiography methods
Number of subjects: 125
Study 34022912 — intervention group
Group type: EXPERIMENTAL
Intervention: House Improvement (HI)
Number of subjects: 20013
Study 34022912 — intervention group
Group type: EXPERIMENTAL
Intervention: Larval Source Management (LSM)
Number of subjects: 20013
Study 34022912 — intervention group
Group type: EXPERIMENTAL
Intervention: House Improvement + Larval Source Management (HI + LSM)
Number of subjects: 20013
Study 34022912 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20013
Study 32221160 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 117
Study 32221160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 34265255 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise (≤6 sessions)
Number of subjects: 708
Study 34265255 — intervention group
Group type: COMPARATOR
Intervention: Best practice advice (one session)
Number of subjects: 708
Study 34265255 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection then progressive exercise
Number of subjects: 708
Study 34265255 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection then best practice advice
Number of subjects: 708
Study 32268257 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented biofeedback training alongside traditional physical therapy
Number of subjects: 45
Study 32268257 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 45
Study 32268257 — intervention group
Group type: COMPARATOR
Intervention: Augmented biofeedback training
Number of subjects: 45
Study 32268257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of augmented biofeedback training and traditional physical therapy
Number of subjects: 45
Study 35334900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk formula (CMF)
Number of subjects: 30
Study 35334900 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric extensive protein hydrolysate formula (EHF)
Number of subjects: 30
Study 35334900 — intervention group
Group type: COMPARATOR
Intervention: EHF
Number of subjects: 30
Study 35334900 — intervention group
Group type: COMPARATOR
Intervention: Clostridia at 3-4 months
Number of subjects: 30
Study 34485754 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride (15 mg/kg) administered intravenously as a bolus at the beginning of weaning from CPB
Number of subjects: 818
Study 34485754 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride administered intravenously as a bolus at the beginning of weaning from CPB
Number of subjects: 818
Study 33607392 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-eveners (≥3 times/week)
Number of subjects: 348
Study 33607392 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-eveners
Number of subjects: 348
Study 33607392 — intervention group
Group type: COMPARATOR
Intervention: Reference group (non-late-eaters)
Number of subjects: 348
Study 34963654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (reduced inappropriate media exposure)
Number of subjects: 613
Study 34963654 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 613
Study 34788233 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP) plus standard care
Number of subjects: 80
Study 34788233 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 80
Study 32703177 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral neuropathy with claw toes
Number of subjects: 40
Study 32703177 — intervention group
Group type: COMPARATOR
Intervention: Peripheral neuropathy without claw toes
Number of subjects: 40
Study 32703177 — intervention group
Group type: COMPARATOR
Intervention: Non-neuropathic with claw toes
Number of subjects: 40
Study 32703177 — intervention group
Group type: COMPARATOR
Intervention: Non-neuropathic without claw toes
Number of subjects: 40
Study 36219509 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGiC
Number of subjects: 0
Study 36219509 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 0
Study 34424563 — intervention group
Group type: EXPERIMENTAL
Intervention: Weed presence from emergence until the two true-leaf stage
Number of subjects: 4